Ultra-Low Doses of Nivolumab Could Revolutionize Cancer Treatment Costs

New research from Tata Memorial Hospital in Mumbai reveals that using ultra-low doses of the immunotherapy drug Nivolumab may significantly reduce cancer treatment costs while maintaining efficacy and minimizing side effects. Conducted on a large scale, the study indicates that a dosage of one-tenth of the standard amount can effectively treat patients with various cancers, including head and neck and lung cancers.

According to the findings, the monthly cost of treatment with Nivolumab could decrease from approximately ₹4.4 lakh to around ₹18,700. The senior author of the study, Dr. Kumar Prabhash, highlighted the importance of this research, which was published in the Journal of Clinical Oncology. It represents the largest randomised study on Nivolumab to date, involving 500 patients with advanced or previously treated cancer.

Study Outcomes and Implications

The research found that the one-year overall survival rate for patients taking Nivolumab was 27.3 percent, compared to 16.9 percent for those receiving standard chemotherapy. Furthermore, the incidence of infections, diarrhoea, and hospitalisations was notably lower among patients treated with the immunotherapy drug.

Experts estimate that nearly 80 percent of cancer patients worldwide cannot access such treatments due to their prohibitive costs. Dr. Prabhash emphasized the goal of identifying the minimum effective dose while maintaining treatment effectiveness. Traditionally, drug development has focused on determining the maximum tolerable dose, which often leads to unnecessarily high treatment costs.

Broader Context of Dose Optimization in India

The Nivolumab trial is part of a broader initiative in India aimed at making expensive treatments more accessible. Similar dose optimization strategies have been applied in vaccination and tuberculosis treatment programs. For instance, India’s recent human papillomavirus (HPV) vaccination campaign recommends a single dose for girls aged 14-15, unlike the two-dose schedule recommended in countries such as the US and UK. Long-term studies from the International Agency for Research on Cancer and the World Health Organization suggest that a single dose can produce sufficient antibody responses.

In tuberculosis treatment, India introduced the BPaL-M regimen in 2025, following a three-year trial aimed at reducing the toxicity associated with the antibiotic linezolid. This new approach modifies the treatment from a daily dose of 600 mg for six months to a regimen of 600 mg for the first 13 weeks, followed by 300 mg for the remainder of the treatment period.

Despite these promising developments, there remains a challenge in implementing such innovations across the healthcare system. Dr. Rajendra Badwe, former director of Tata Memorial Centre, pointed out that many private hospitals continue to adhere to the original dosage protocols established during early clinical trials. He noted that cost-effective treatment strategies are crucial, especially for middle-class patients grappling with the financial burden of cancer care.

Another example of successful dose optimization is a study led by Dr. Sudeep Gupta on the antibody drug Trastuzumab for HER2-positive breast cancer. This research demonstrated that a three-month course of therapy could yield results comparable to the standard one-year treatment. While Tata Memorial Hospital has adopted this shorter protocol, many private facilities have yet to follow suit.

As the medical community continues to explore these innovative approaches, the findings from Tata Memorial Hospital could pave the way for more affordable and accessible cancer treatments worldwide. The focus on optimizing drug dosages not only aims to enhance patient outcomes but also strives to make essential therapies available to a broader population.